Abstract Neoadjuvant ipilimumab+ nivolumab (Ipi+ Nivo) and nivolumab+ chemotherapy
(Nivo+ CT) induce greater pathologic response rates than CT alone in patients with …

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-
small cell lung cancer (NSCLC), but its efficacy and impact on the immune …

8504 Background: Neoadjuvant immune checkpoint inhibitors (ICIs) induce major
pathologic response (MPR) rates of 20 to 45% in resected NSCLCs. We report the results of …

Background We conducted the first trial of neoadjuvant PD-1 blockade in resectable non-
small cell lung cancer (NSCLC), finding nivolumab monotherapy to be safe and feasible with …

Background Standard treatment with neoadjuvant nivolumab plus chemotherapy
significantly improves outcomes in patients with resectable non–small-cell lung cancer …

Abstract Purpose: Neoadjuvant anti–PD-1 therapy has shown promise for resectable non–
small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant …

Background In patients (pts) with non-metastatic NSCLC, surgery has curative potential but
30-80% who undergo resection experience recurrence. Neoadjuvant or adjuvant chemo is …

Background Neoadjuvant or adjuvant chemotherapy confers a modest benefit over surgery
alone for resectable non–small-cell lung cancer (NSCLC). In early-phase trials, nivolumab …

PURPOSE Neoadjuvant chemotherapy plus nivolumab has been shown to be effective in
resectable non–small-cell lung cancer (NSCLC) in the NADIM trial (ClinicalTrials. gov …

8503 Background: CheckMate 816 (NCT02998528) is a randomized phase 3 study of
neoadjuvant NIVO+ chemo vs chemo in resectable NSCLC. The study met its first primary …